Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine M Kelly

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Frontiers in Oncology|September 22, 2022
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trialKatya Galactionova, Sibylle Loibl, Paola Salari, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in IrelandLynda M McSorley, Mehala Tharmabala, Fathiya Al Rahbi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast CancerIan Krop, Vandana Abramson, Marco Colleoni, et al.
Cancers|April 3, 2021
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER"Niamh M Keegan, Simon J Furney, Janice M Walshe, et al.
NPJ Breast Cancer|September 29, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancerJustin M Balko, Luca Licata, Xiao Qian Wang, et al.
Nature|September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancerXiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2021
Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factorsSeodhna M Lynch, Niamh M Russell, Stephen Barron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2021
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B TrialSibylle Loibl, Frederik Marmé, Miguel Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerMatteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
JCO Precision Oncology|September 2, 2025
Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment StrategiesEric Hahnen, Jan Hauke, Karen Gelmon, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Frontiers in Oncology|September 22, 2022
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trialKatya Galactionova, Sibylle Loibl, Paola Salari, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in IrelandLynda M McSorley, Mehala Tharmabala, Fathiya Al Rahbi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast CancerIan Krop, Vandana Abramson, Marco Colleoni, et al.
Cancers|April 3, 2021
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER"Niamh M Keegan, Simon J Furney, Janice M Walshe, et al.
NPJ Breast Cancer|September 29, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancerJustin M Balko, Luca Licata, Xiao Qian Wang, et al.
Nature|September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancerXiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2021
Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factorsSeodhna M Lynch, Niamh M Russell, Stephen Barron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2021
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B TrialSibylle Loibl, Frederik Marmé, Miguel Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerMatteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
JCO Precision Oncology|September 2, 2025
Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment StrategiesEric Hahnen, Jan Hauke, Karen Gelmon, et al.
Pageof 7